An oral compound designed to replicate the metabolic effects of exercise — fat loss, muscle preservation, improved metabolism — has just dosed its first subjects in a human trial out of the University of Copenhagen.

ATR-258, developed by Stockholm-based Atrogi, is a GRK2-biased β2-agonist, meaning it selectively activates downstream muscle-building signaling without triggering the cardiovascular side effects that made previous β2-agonists a non-starter for chronic use. Safety and tolerability were already established in a 69-subject Phase 1 trial, published alongside mechanistic validation in Cell last June. This new 8-week interventional study in overweight male volunteers is specifically hunting for muscle physiology data — biopsies, molecular readouts, functional measures — the kind that would support use across immobilization, aging, and weight-loss-related muscle wasting.

The underappreciated angle: This isn't another GLP-1 adjacent obesity play. The explicit goal is muscle-sparing weight loss, which is exactly the gap the GLP-1 era opened and hasn't closed.

Open question: Overweight men only, 8 weeks — a narrow window. Generalizability and longer-term metabolic outcomes remain unwritten.

Your move: Keep ATR-258 on your radar if you're following the muscle-loss-during-weight-loss problem. Results expected later this year.

Source: Atrogi